

ASX ANNOUNCEMENT

Actinogen to Present to Investors in Singapore and Sydney

- Dr Bill Ketelbey, CEO, presenting business update to investors, including institutional investors, family offices and hedge funds in Singapore and Sydney
- Presentation attached with latest progress and milestones achieved
- XanADu update: 145 patients enrolled out of the 174 target, representing 83% of the total
- XanADu: only 29 more patients to enrol. On track to complete enrolment before year-end and to report out results in Q2 2019
- A number of new studies supporting the development of Xanamem already underway or soon to initiate, including target occupancy, higher dose safety and multiple safety toxicology studies.

Sydney, 11 September 2018. Actinogen Medical (ASX: ACW) CEO, Dr Bill Ketelbey, will present a business update at the *Singapore Healthcare Investor Day* on the 12th of September 2018 and the *Financial News Network Investor Conference* on the 18th of September 2018 in Sydney. A copy of the presentation to be delivered is attached.

At the *Healthcare Investor Day*, Actinogen will present to leading Singapore-based hedge funds, family offices and institutional investors and hold a series of one to one investor meetings.

Along with the Australian market, Singapore is an important region for life sciences investment with a large number of sophisticated investors focused on the sector. It is a gateway to Asia and has emerged as the Asian capital for biotech and med-tech development following government backed initiatives aimed at promoting and attracting leading scientists and researchers to the country.

Singapore also has a high prevalence of people with dementia aged 60 years and over. It has been estimated that one in every ten people aged over 60 years in Singapore has some form of dementia¹ and by 2020 it is anticipated that over 50,000 people will be diagnosed with dementia².

At both investor conferences, Dr Ketelbey will present a business update on Actinogen with the latest progress and milestones achieved. Most significantly, he will provide an update on the excellent progress being made with XanADu, the Company's clinical trial of its lead compound, Xanamem, in Alzheimer's disease. Currently there are 145 patients enrolled out of the target of 174, representing 83% of the total. At the current rate of enrolment, the final patient is expected to be enrolled before the end of the year, resulting in top-line results from the study in Q2 next year, less than 12 months from now.

Dr Ketelbey will also update the market on the Company's expanded development plans for Xanamem. Following the successful capital raise in May 2018, that included strong institutional support, the Company announced a number of new studies, including a target occupancy study that is already underway. Further additional studies will begin in Q4 of this calendar year and will include a higher dose safety study and multiple safety toxicology studies to support the development of Xanamem.

ENDS

¹ Singapore Elderly (WISE) study

² Alzheimer's Disease Association (Singapore)

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Media Enquiries

Imogen Conyers
Media & Capital Partners
M: +61 405 191 257
E: imogen.conyers@mcpartners.com.au

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.